TVM Capital
Venture Capital
Active
Munich, Germany
102
19M
55
2.55
13
0.46
32
- Stages of investment
- Areas of investment
Summary
TVM Capital is the famous VC, which was founded in 1983. The fund was located in Europe if to be more exact in Germany. The main department of described VC is located in the Munich.
The important activity for fund was in 2007. The typical startup value when the investment from TVM Capital is 10-50 millions dollars. The fund is constantly included in 2-6 deals per year. Deals in the range of 10 - 50 millions dollars are the general things for fund. Comparing to the other companies, this TVM Capital performs on 0 percentage points more the average number of lead investments. Considering the real fund results, this VC is 1 percentage points less often commits exit comparing to other organizations. The higher amount of exits for fund were in 2014.
This organization was formed by Rolf Christof Dienst. We also calculated 6 valuable employees in our database.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Vivoryon Therapeutics, Rapid Micro Biosystems, VPIsystems. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. Among the most successful fund investment fields, there are Pharmaceutical, Manufacturing.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the TVM Capital, startups are often financed by Atlas Venture, Crescendo Ventures, 3i Group. The meaningful sponsors for the fund in investment in the same round are Skyline Ventures, Atlas Venture, Next47. In the next rounds fund is usually obtained by Skyline Ventures, Longitude Capital, Intersouth Partners.
Investor highlights
- Industry focus
- Stage focus
- Geo focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Last fund
- Fund size
- USD 250000000
- Fund raised date
- 2024-05-28
Analytics
- Total investments
- 102
- Lead investments
- 13
- Exits
- 32
- Rounds per year
- 2.55
- Follow on index
- 0.46
- Investments by industry
- Biotechnology (57)
- Health Care (30)
- Pharmaceutical (27)
- Software (20)
- Medical (16) Show 50 more
- Investments by region
-
- United States (57)
- Germany (21)
- United Kingdom (10)
- France (2)
- Switzerland (2) Show 6 more
- Peak activity year
- 2008
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 21
- Avg. valuation at time of investment
- 48M
- Group Appearance index
- 0.97
- Avg. company exit year
- 12
- Avg. multiplicator
- 2.05
- Strategy success index
- 0.40
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Abionyx Pharma | 25 Jul 2010 | Biotechnology, Health Care | Late Stage Venture | 59M | Midi-Pyrenees, Balma, France |
audiobridge | 13 May 2020 | Mobile, Music, iOS, Audio | Seed | 68K | United States, California, Oakland |
Morphics Technology | 29 Jan 2001 | Intellectual Property, Wireless, DSP, Communications Infrastructure | Late Stage Venture | 44M | United States, California |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.